

Media	Lianhe Zaobao	Date	6 Nov 03
Section			

## 干细胞公司二度集资获700万

本地干细胞生物科技公司康盛人生(Cordlife) 成功在第二轮集资活动中,筹得700万元的资金。目前,公司的总资金已达1140万元。

公司将利用所筹得的资金,扩展它在中国、澳洲和美国的业务。同时,公司也会把资金用在扩大干细胞和 T 细胞研究方面的用途,预计这些试验性研究将为期一年。

康盛人生是本地第一家私营脐带血库,它主要负责处理和保存于细胞。

CordLife today announced that it had successfully closed its Series B round with an investment of S\$7 million. The total investment in CordLife to date has been S\$11.4 million.

The funds will be used to expand its business base in China, Australia and the US. It will also be used to fund Phase I and II clinical trials in ex vivo stem cell and T cell expansion. These trials will be conducted in collaboration with the US Food & Drug Administration (FDA) and the Australian government. These trials will begin when the relevant regulatory approvals have been granted, and are expected to last about 12 months.